


# Mpox Guideline Development Group

## Biographies

---

Version 2.0

26 November 2024



# Overview

For the development of the *Clinical management and infection prevention and control for mpox*, a Guideline Development Group (GDG) comprising individuals with broad expertise spanning multiple specialties and all regions was convened. This group includes patient panel members.

The technical unit collected and managed declarations of interests (DOIs) which were declared upon becoming a group member and at each meeting.

WHO wishes to acknowledge all the experts that contributed to the GDG and to thank them for their commitment and support to achieve the evidence-based recommendations for care of patients with mpox.



## Pierre Abi Hanna

Pierre Abi Hanna is a board-certified in internal medicine and infectious diseases. Currently, he serves as Head of the Infectious Diseases Division at the Lebanese University, Faculty of Medical Sciences, and at Rafik Hariri University Hospital (RHUH). Additionally, he is a member of the National Committee of Communicable Diseases, a consulting body for the Ministry of Public Health. His practice includes clinical infectious disease management, infection prevention and control (IPC) and teaching activities. RHUH has been the main referral hospital for mpox cases, handling diagnosis and management. It has seen a total of 28 referred patients, all but one of whom were managed as outpatients. Beyond his hospital work, he collaborates with a nongovernmental organization (NGO) focused on sexual health, where he provides clinical consultations and conducts two sexually transmitted diseases (STD) clinics a month. He also manages an HIV practice within his clinic, which has evolved into a de facto primary care service for many of these patients.

Additionally, he chairs the IPC committees at RHUH and another private hospital. As part of his role, he is actively involved in training programmes focused on communicable diseases, IPC and managing local epidemics. These activities ensure that health care professionals are well equipped to address emerging and ongoing public health challenges.

For DOI, see the Annex.



## Mary Adanma Alex-Wele

Mary Adanma Alex-Wele is a medical doctor and consultant clinical microbiologist with specialization in IPC. She currently serves as the Chair of the Department of Medical Microbiology and Parasitology, and the AMR and IPC Programme Focal Person at the University of Port Harcourt Teaching Hospital, Nigeria. She was responsible for setting up the IPC programme of the hospital and developing guidelines. She has driven health care delivery in Nigeria and beyond, serving as a the WHO Africa Region consultant and advancing infection control through her work on emergency preparedness with the African Volunteer Health Corps on Strengthening and Utilizing Response Groups for Emergencies. She is a member of the Orange Network, the national IPC/AMR network in Nigeria and has various engagements with the Nigeria Centre for Disease Control. Her work on epidemic response and AMR, including contributions to WHO guidelines and IPC in low-resource settings, underscores her impact on global health security.

She is also a Senior Lecturer at the University of Port Harcourt, where she mentors younger colleagues aspiring to be medical doctors. She

has several research interests in areas concerning IPC, AMR, emerging and re-emerging infectious diseases and is well published.

For DOI, see the Annex.



## Nawal Al Kaabi

Nawal Al Kaabi is a paediatric infectious diseases consultant at Sheikh Khalifa Medical City, United Arab Emirates. Since 2012 she has been Chair of the SEHA Infectious Diseases and Infection Control Council. She was Chief Medical Officer at Sheikh Khalifa Medical City March 2017–2022 and Chair of the National COVID-19 Clinical Committee from 2020. She is also a senior advisor to Hayat Biotech. Nawal Al Kaabi is the Principal Investigator (PI) of multiple clinical trials. Her main interests are vaccination, emerging infectious diseases, clinical trials, research, infection control, medical education and childhood issues.

For DOI, see the Annex.



## Meaghen Allen

Meaghen Allen is a certified public health inspector working in Alberta, Canada. She currently sits on the Canadian Institute of Public Health Inspectors National Executive Council and is the Canadian Institute of Public Health Inspectors Alberta Branch President. Her areas of interest include community infection control, vulnerable populations and the built environment. Meaghen has a BSc from the University of Alberta, an after-degree in environmental public health, and a master's in public health management. Meaghen currently works as the Director of Safe Healthy Environments with Alberta Health Services.

For DOI, see the Annex.



## Javier Hourcade Bellocq

Javier Hourcade Bellocq has had an extensive career as a communicator in health, rights and HIV advocacy. Since his HIV-positive diagnosis in 1988, he has worked with civil society, key populations and communities living with HIV, tuberculosis (TB) and viral hepatitis in Latin America and beyond. Hourcade Bellocq has been involved with The Global Fund for two decades, in the Communities and Latin America and Caribbean Constituencies of the Global Fund Board. He founded and led since 2009 a community journalism initiative called the LAC Key Correspondent Team based in Peru. He is Board Member of the Communities Delegation at The

Global Fund Board as well as member of the Strategy Committee. He is currently collaborating with the Pan American Health Organization advanced HIV disease project on community engagement.

For DOI, see the Annex.



## Lars Bode

Lars Bode is Professor of Pediatrics, Chair of Collaborative Human Milk Research and the founding Director of the Mother-Milk-Infant Center of Research Excellence and the Human Milk Institute at the University of California, San Diego.

Dr Bode received both his MSc and PhD in Nutritional Sciences from the Justus-Liebig University Giessen, Germany, and completed a pre-doctoral fellowship at the Institute of Child Health, University College London, United Kingdom, in 2003. Following a postdoctoral fellowship at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, Dr Bode joined the faculty at the University of California, San Diego, in 2009.

Currently, Dr Bode is leading a research programme dedicated to research on breastfeeding and human milk in general and human milk oligosaccharides in particular. His main research objectives are to elucidate: how milk components are synthesized in the mother's mammary gland; how milk composition is affected by external factors such as nutrition, pathogens or medications; how milk components affect immediate as well as long-term health and development of infants and mothers; and how milk components can serve as natural templates for the development of preventatives, therapeutics and diagnostics for people of all ages.

For DOI, see the Annex.



## Andre Bulabula

Andre Bulabula is a medical doctor with specialist training in IPC and a clinical epidemiologist with a PhD in public health. He has extensive experience in developing IPC training materials, guidelines and programmes, and currently serves as a senior technical officer at the Africa Centres for Disease Control and Prevention. He is also a university lecturer, conference speaker and expert in antimicrobial resistance (AMR) research.

For DOI, see the Annex.



## Shama Cash-Goldwasser

Shama Cash-Goldwasser, MD, MPH, is an infectious diseases physician and epidemiologist with expertise in emerging and zoonotic infectious diseases. She is currently a medical officer in the Pox and Rabies Branch at the US Centers for Disease Control and Prevention (CDC), where she leads the agency's Mpox Clinical Consultation Team and the Virologic and Immunologic Characteristics of Severe Mpox in Patients with Advanced HIV (VIRISMAP) study.

For DOI, see the Annex.



## Mark Cotton

Mark Cotton is an emeritus professor at Stellenbosch University. He trained in Paediatric Infectious Diseases in Denver, CO between 1991 and 1994. He led the Family Centre for Clinical Research (FAMCRU) as a PACTG and IMPAACT investigator between 2001 and 2021. He participated in several pivotal clinical trials in children, both on ART strategy (CHER), isoniazid prophylaxis and ARV pharmacokinetics. He leads the South African component of PAVE (Pediatric HIV Elimination), funded by NIAID through the Martin Delaney Collaboratory and he is working on HIV remission studies in children through IMPAACT. Since December 2022, he is chief editor of the Southern African Journal of Infectious Diseases.

For DOI, see the Annex.



## Jake Dunning

Jake Dunning is Consultant Physician and Associate Professor in Infectious Diseases, and the Lead for High Consequence Infectious Diseases (HCID) at the Royal Free Hospital, London. He is also Director of the NHS England Network for Contact HCIDs and an honorary consultant in emergency preparedness, resilience and response (EPRR) at the UK Health Security Agency. He conducts research into emerging infections, zoonoses, acute respiratory infections and HCIDs, including mpox, at the Pandemic Sciences Institute, University of Oxford. His international research covers virology, pathogenesis, transmission, IPC, clinical characterization, diagnostics, treatments and supportive care, and prevention. He contributes to a variety of national and international infectious disease guidelines. Jake Dunning is a long-term investigator in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) and has worked on its clinical characterization protocols since 2012.

For DOI, see the Annex.



## Tom Fletcher

Tom Fletcher is an infectious diseases physician based at the Liverpool School of Tropical Medicine and the Pandemic Institute in Liverpool. Specialized in the management and research of HCID, he has previously supported WHO with outbreak response, leading clinical teams in the West African Ebola outbreak. His research currently is focused on clinical trials of novel therapeutics and diagnostics in COVID-19 and viral haemorrhagic fevers. He has managed cases of mpox as part of the UK HCID network. Dr Fletcher is the Co-Chair of the Mpox GDG.

For DOI, see the Annex.



## Esther Freeman

Esther Freeman, MD, PhD, is Director of Global Health Dermatology at Massachusetts General Hospital, Harvard Medical School. She also serves as the Director of Clinical Innovation and Education for the Center for Global Health at Massachusetts General Hospital. As founding and immediate past Chair of the International Alliance for Global Health Dermatology (GLODERM), she developed an international mentorship programme for dermatology changemakers from under-resourced settings. She is Vice-Chair of the International Foundation for Dermatology, which is the foundation arm of the International League of Dermatologic Societies (ILDS). Her work as a physician-scientist and epidemiologist focuses on access to care and infectious diseases affecting underserved populations globally. She is the PI of the American Academy of Dermatology and ILDS registry for COVID-19, mpox and emerging infections, and has won two presidential citations from the American Academy of Dermatology for her work. She has been a consultant to WHO. She focuses on infectious disease dermatology and global health dermatology, including outbreaks such as mpox, COVID-19 and tinea. In addition to over 100 scientific papers, some of which have been viewed more than 1 million times in the *New England Journal of Medicine*, her work has been cited extensively in the lay press, including the *New York Times*, *Washington Post* and *National Geographic*.

For DOI, see the Annex.





## Carole Fry

Carole Fry is the strategic lead for IPC at the UK Health Security Agency. Previous roles include Technical Officer for IPC at WHO headquarters working on COVID-19, Nurse Advisor for Communicable Diseases at the Department of Health (England), Deputy Director for the HCID Programme within Public Health England (PHE) and Strategic Lead for AMR at PHE. Carole also has extensive frontline experience working in IPC in the NHS. Carole has contributed to several national working parties developing evidence-based guidelines and a number of national expert committees related to IPC and AMR. She is a trustee of the UK Infection Prevention Society. She sits on the international editorial board of the *Journal of Hospital Infection*.

For DOI, see the Annex.



## Michelle Giles

Michelle Giles is an infectious diseases physician and a professor in the Department of Obstetrics and Gynaecology, Monash University and Department of Infectious Diseases, University of Melbourne. Her clinical infectious diseases practice is at the Royal Women's Hospital, Alfred Health, Monash Health and Western Health, Melbourne. Her clinical work focuses on infections in pregnancy and bloodborne viruses, particularly HIV. Her current research programme spans basic science with a focus on non-specific effects of maternal immunization on pregnancy and clinical implementation research related to delivery of evidence-based care in pregnancy. Michelle Giles has been on the National COVID-19 Clinical Evidence Taskforce Pregnancy and Perinatal Care Panel since its inception, is Deputy Chair of the Australian Technical Advisory Group on Immunisation (ATAGI), Co-Chair of the ATAGI COVID-19 Working Group, and has held a number of advisory roles with WHO including, most recently, being appointed to the WHO Technical Advisory Group on Group B Streptococcus Vaccine Development (TAG-GBS).

For DOI, see the Annex.





## Beatriz Grinsztejn

Beatriz Grinsztejn is an infectious disease physician and researcher with over 30 years dedicated to the prevention and care of infectious diseases, especially HIV and sexually transmitted infections (STIs). She is Director of the FIOCRUZ STI/AIDS Prevention and Therapeutic Clinical Trials Unit, affiliated with major international networks, including the HIV Prevention Trials Network (HPTN) and AIDS Clinical Trials Group (ACTG). She is the Co-Chair of the HPTN 083 Study and the UNITY trial, and Chair of the ImPrEP CAB-LA Implementation Study. She was honoured with the HPTN Ward Cates Spirit Award (2021) and the ACTG James Hakim Award (2022) and delivered the N’Galy-Mann Lecture at CROI in 2022. Dr Grinsztejn is the current President-elect of the International AIDS Society. Since the 2022 mpox surge, she has been at the forefront of research and response efforts, focusing on generating critical knowledge to guide public health strategies, with a focus on populations at higher vulnerability, including men who have sex with men and transgender individuals.

For DOI, see the Annex.



## Ahmed Hakawi

Ahmed Hakawi is a senior public health expert and consultant in infectious diseases at the Public Health Authority, Saudi Arabia. He has 18 years’ experience as an infectious disease physician, infection control lead, hospital epidemiologist and public health expert and has worked for many national and international scientific committees in infectious diseases, IPC and public health. He held several leadership positions including leading the country’s communicable disease control administration for several years and has a special interest in respiratory pathogens, multidrug-resistant organisms, neglected tropical diseases and IPC.

He is currently working as an advisor for communicable disease control in the Public Health Authority, Saudi Arabia. He also is a public health influencer on social media.

For DOI, see the Annex.



## Lisa Hensley

Lisa Hensley serves as Director of the Zoonotic and Emerging Disease Research Unit for the US Department of Agriculture. She has an extensive background in public health, obtaining her PhD at the University of North Carolina at Chapel Hill and a master's in immunology and infectious disease from the Bloomberg School of Public Health, Johns Hopkins University. She has spent the last 20 years developing and characterizing animal models for high consequence and emerging pathogens. She is considered one of the world's leading subject matter experts on emerging diseases and high consequence pathogens. She is one of the few scientists with experience in the development of medical countermeasures, from in vitro to pre-clinical and clinical trials. She has authored over 200 peer reviewed scientific papers and book chapters and is a holder of multiple patents.

For DOI, see the Annex.



## Prince Imani-Musimwa

Prince Imani-Musimwa is a Congolese doctor, obstetrician-gynaecologist and epidemiologist with extensive experience of providing healthcare to pregnant and breastfeeding women, as well as infants, in Ebola and Covid-19 Treatment Units during respectively the last six Ebola epidemics and Covid-19 pandemic in the Democratic Republic of the Congo (DRC). This experience also extends to rapid implementation and management of response to outbreaks and other emergencies. He is specialized in gender based violence, in sexual and reproductive health, including maternal and child health promotion—encompassing prevention, care, and follow-up—within the context of epidemics caused by highly contagious pathogens and humanitarian crises in the DRC. He is a PhD student, lecturer, and researcher at the University of Goma, and serves as the Director of the Center of Research Expertise and Health Promotion (CREHP), DRC. In February 2022, as an expert in the management of Ebola virus disease, he was invited by the World Health Organization (WHO/HQ) to review the training modules for the advanced management of Ebola virus disease, and this was done. Currently, he is involved in the Mpox outbreak response as senior researcher and case management supervisor with a focus on mother-and-child health in mpox outbreak.

For DOI, see the Annex.



## Jason Kindrachuk

Jason Kindrachuk is an associate professor and Canada Research Chair in Emerging Virus Pathogenesis in the Department of Medical Microbiology and Infectious Diseases, and is cross appointed in the Department of Internal Medicine and the Manitoba Centre for Proteomics and Systems Biology, University of Manitoba. His work focuses on viruses that pose the greatest threat to global health including orthopoxviruses, ebolaviruses, coronaviruses and influenza viruses. His research programme centres on the circulation, transmission and pathogenesis of emerging viruses. Past and present findings from these investigations will help inform emerging virus therapeutic treatment strategies, outbreak prediction and preparedness efforts with impacts on both human and animal health. Dr Kindrachuk leads multiple nationally funded emerging infectious disease research investigations with a particular focus on sub-Saharan Africa. These include as Director for the International Mpox Response Consortium and in ongoing investigations on the long-term impacts of Ebola virus infection in disease survivors in West Africa.

For DOI, see the Annex.



## Jayatilleke Kushlani

Jayatilleke Kushlani is a consultant microbiologist for the Sri Jayewardenepura General Hospital, Nugegoda, Sri Lanka. She obtained a postgraduate diploma and medical degree in medical microbiology from Lancashire Teaching Hospitals NHS Trust, United Kingdom.

She is currently working as an expert advising the Sri Lanka Ministry of Health on AMR and is part of the team involved with the National Surveillance of AMR for Global Antimicrobial Surveillance System. She is the author of many publications and presentations on AMR and IPC related topics. She is now a trainer and an examiner in many undergraduate and postgraduate programmes including MD, PhD and MPhil in microbiology, and a reviewer for many journals including *BMJ Open* and *Annals of Clinical Microbiology and Antimicrobials*.

For DOI, see the Annex.



## Fernanda Lessa

Dr Lessa is Chief of the International Infection Control Branch (IICB) at US CDC. She received her medical degree in Brazil where she served as an infectious disease physician and hospital epidemiologist. She has a master's in public health from the University of California Berkeley School of Public Health. She has published over 70 peer-reviewed papers and authored several book chapters on infectious diseases epidemiology.

Dr Lessa has extensive experience in health care epidemiology in the United States and abroad. She has led population-based surveillance programmes for *Clostridioides difficile* and methicillin-resistant *Staphylococcus aureus* in the United States, the Global Pneumococcal Program working with pneumococcal vaccine implementation and evaluation across Latin America, Africa and South-East Asia, and has overseen implementation of the Global Action in Healthcare Network for rapid detection, prevention and response of emerging infectious diseases threats in health care settings globally.

For DOI, see the Annex.



## Laurens Liesenborghs

Laurens Liesenborghs is an infectious disease specialist and researcher specialized in emerging infectious disease and humanitarian medicine. He has a diverse scientific background in key areas of infectious diseases, including preclinical drug development, virology, vaccinology, microbiology, clinical trials and epidemiology.

During his PhD, he developed a novel preclinical model to study the pathophysiology of infective endocarditis. His focus later shifted to emerging viruses, beginning with his work for Doctors Without Borders on a Lassa fever project in Sierra Leone. He then conducted postdoctoral research at the BSL3+ lab at KU Leuven, where he contributed to the development of a hamster model for COVID-19 and worked on testing antivirals and vaccines for SARS-CoV-2.

Currently, Laurens is an assistant professor at the Institute of Tropical Medicine and KU Leuven. His research primarily focuses on mpox. He has been co-leading a major project on mpox transmission in the Democratic Republic of the Congo, where his team discovered the Clade Ib variant responsible for the 2024 multicounty outbreak. In Belgium, he is conducting several studies on mpox, including on asymptomatic presentations, high-risk contacts and diagnostics, as well as participating in clinical trials on therapeutics. His broader research includes outbreaks and haemorrhagic fevers in Africa.

For DOI, see the Annex.



## Kalisvar Marimuthu

Dr Kalisvar Marimuthu leads the National Infection Control and Healthcare Epidemiology Division of Singapore's interim Communicable Diseases Agency, and is Head of the Infection Prevention, Control, and Outreach Division at the National Centre for Infectious Diseases. He serves as Senior Consultant in Infectious Diseases at Tan Tock Seng Hospital, Singapore, and chairs the national IPC committee. Dr Marimuthu graduated with a medical degree from the University of Malaya in 2003 and became a member of the Royal College of Physicians (United Kingdom) in 2006. He completed his advanced specialty training in internal medicine and infectious diseases in Singapore in 2010 and 2013, respectively. His commitment to infection prevention led him to train as a senior research fellow in the IPC Unit at Geneva University Hospital. His research centres on the transmission dynamics of emerging infectious diseases and multidrug-resistant organisms. His work extends to health care-associated infection surveillance and prevention strategies, with a special focus on leveraging genomics in IPC.

For DOI, see the Annex.



## Geeta Mehta

Geeta Mehta initiated, developed and led IPC programmes in major public sector teaching hospitals affiliated to Delhi University. She trained medical and nursing students in IPC, curriculum development and research. Her last position was Director Professor and Head of Clinical Microbiology, Lady Hardinge Medical College, New Delhi. She is the founder member of the Hospital Infection Society India (President 2006–2010), and a member/advisor on Government of India committees/programmes/projects on IPC and related issues. She developed the national IPC guideline and has contributed to many WHO IPC guidelines. She was on the board of Directors of International Federation of Infection Control between 2004 and 2008.

For DOI, see the Annex.



## Graeme Meintjes

Graeme Meintjes is Clinical Professor of Infectious Diseases at Queen Mary University London and a Professor of Medicine at the University of Cape Town (UCT). He is an adult infectious diseases specialist. He leads a research programme focusing on the clinical conditions affecting patients with advanced HIV disease including disseminated HIV-associated TB, the immune reconstitution inflammatory syndrome and cryptococcal meningitis. His group also investigates drug-resistant TB, diagnostics for TB and antiretroviral therapy strategies. He has been the PI or local PI of several clinical trials and conducts observational cohort studies that address questions related to disease pathogenesis. He has contributed to the development of management guidelines for HIV, TB and cryptococcal meningitis at a provincial and national level and in WHO GDGs. He previously held the SARCHI Chair of Poverty-related Infections at UCT (2015–2023) and was Deputy Head of the Department of Medicine at UCT (2020–2024). He has authored over 370 publications in peer-reviewed journals and 17 book chapters.

For DOI, see the Annex.



## Sharon Nachman

Sharon Nachman is the Chief of the Division of Pediatric Infectious Disease at Stony Brook Children's Hospital. She is also the Vice Dean for Research at the Renaissance School of Medicine at Stony Brook, and directs the Office of Clinical Trials at the institution. As the PI and Chair of the IMPAACT Network ([www.impaactnetwork.org](http://www.impaactnetwork.org)), she has developed and directed the maternal and child HIV and TB clinical trial agendas for the past 10 years. She has had leadership roles in over 25 clinical trials, including 20 as either protocol chair or vice chair. All studies have enrolled, analyzed, and published results that have changed the way we evaluate and treat a host of infectious disease illnesses affecting children and women worldwide. In addition to her focus on HIV and TB, she also developed studies helping to define the dose and PK for new antibiotics and antivirals, evaluate new vaccines, and understand the long term issues that develop in infants born to HIV+ women worldwide.

For DOI, see the Annex.





## Emmanuel Nakoune

Emmanuel Nakoune-Yandoko is Director of Research, Acting Director of the Pasteur Institute of Bangui and Research Professor at the University of Bangui in Central African Republic. He worked extensively for 36 years on arboviruses, viral haemorrhagic fevers, emerging viruses and zoonoses.

His work on the reservoir of the Ebola virus and has demonstrated for the first time in 1998 the genome of the Ebola virus in small mammals captured in the primary forest of Central Africa. His various research works have earned him the following honours: Officer in the Order of Academic Palms (France), Knight in the National Order of Merit (France), and Commander in the National Order of Merit and Commander in the National Order of Recognition (Central African Republic). He won the Rodolphe and Mérieux 2024 award: Impact of Climate Change on the Arboviruses Transmitted by *Aedes aegypti* and *Ae. albopictus* and is an expert member of the African Rabies Network. Emmanuel has been working intensively on mpox in collaboration with the Ministry of Health since 2001 and has been an expert at WHO for mpox since 2018. He has a total of 123 scientific publications in the field of virology in very good peer-reviewed journals.

For DOI, see the Annex.



## Grace Ndeezi

Grace Ndeezi is Professor of Paediatrics and Child Health at Makerere University College of Health Sciences, Uganda, with more than 25 years' experience in research, clinical paediatrics and teaching. She is a practising clinician at the Mulago National Referral Hospital where she leads one of the paediatric wards. For many years she was a trainer for Integrated Management of Childhood Illness. She has more than 160 publications in peer-reviewed journals, and has supervised more than 40 master's and several PhD students to completion.

Dr Ndeezi has a wide experience in the conduct of both hospital-based and community studies. She was PI of a multisite intervention study of multiple micronutrient supplementation in HIV-infected children in Uganda (2005–2008) (NCT00122941). She has been a co-investigator of several randomized trials (NCT00122941, NCT00397150, NCT02605369, NCT02606526) and a multicountry study promoting exclusive breastfeeding in HIV exposed infants (2006–2011) (NCT00640263). Currently, she is the Uganda site investigator of the BRANCH study (Nutritional Management of Growth Faltering in Infants Aged Under Six Months in Asia and Africa: An Individually Randomized Trial) sponsored by WHO. She has participated in other multicountry research grants with partners from Tufts University, the University of Bergen, University of Montpellier,

University of Copenhagen, Karolinska Institute, University of Zambia and Center Muraz in Burkina Faso.

For DOI, see the Annex.




## Bartholomew Boniface Ochonye

Bartholomew Boniface Ochonye is one of Nigeria's foremost human rights and public health programme specialists with over 25 years' experience working at the intersection of health and human rights. Bartholomew has served in various capacities, local and international, including on the 2019 National Technical Committee for Nigeria's Integrated Behavioural and Biological Surveillance Survey. He is a member of the Technical Committee for the Nigeria Mode of Transmission (MOT) study in 2020 and a member of the National Prevention Technical Working Group. He worked as Country Director for Heartland Alliance International (2012–2019) and since 2019 has been CEO of Heartland Alliance LTD/GTE Nigeria. He has also worked with Rockefeller Foundation - Winrock International, AIDS Impact Mitigation project, FHI360-Deliotte consortium ENCAP as Regional Coordinator in 2010, US-CDC/Nigeria as Prevention Specialist in 2011, CEDPA/Nigeria 2006–2009, V4C-Palladium-DFID, USAID-IMHIPP, USAID KP-CARE 1, USAID ACE-6 Comprehensive Treatment Program, and others.

He leads one of the largest key populations programme globally and a comprehensive treatment programme for general and priority populations including adolescents and young persons, providing antiretroviral therapy to over 150 000 people living with HIV in Nigeria. He works on integrating gender and human rights, harm reduction and do no harm principles in all public health interventions and ensuring that mpox, viral hepatitis, cervical cancer screening, access to justice, and HIV/TB co-infection are also prioritized.

For DOI, see the Annex.



## Pius Okong

Pius Okong is a senior consultant obstetrician and gynaecologist in Uganda. He is a medical doctor, with a PhD from the Karolinska Institute, and a founder of Save the Mothers in Uganda and a Master of Public Health Leadership at the Uganda Christian University. Since 2012, Dr Okong has been Chair of the Health Service Commission, which is responsible for the public sector health workforce in Uganda, recruitment of emergency health workers for the COVID-19 pandemic and which follows up human resources issues in epidemics.

Dr Okong is currently a member WHO Technical Working Group on Maternal and Perinatal Death Surveillance and Response, WHO

Steering Committee on the postpartum haemorrhage definition, and FIGO Committee on Health Systems Strengthening and Respectful care. Significant areas of research include HIV, HPV, CMV, HSV and maternal and women's health. He has 56 publications in peer-reviewed journals and has contributed to book chapters. He was a former member of the WHO Mpox GDG. He was honoured by the *Lancet* and Women Deliver for significant contributions to safe motherhood.

For DOI, see the Annex.



## Tochi Okwor

Tochi Okwor is the AMR and IPC Programme Coordinator at the Nigeria Centre for Disease Control. She also chairs Nigeria's National AMR Coordination Committee. She has led the development of numerous national IPC guidance documents including the first national IPC manual, national guidelines on IPC for viral haemorrhagic fevers, various COVID-19 IPC guidance documents and the IPC section of Nigeria's National Mpox Response Guidelines and leads the national IPC policy working group. Tochi Okwor is a graduate of the College of Medicine, University of Nigeria, with an MPH from the University of Lagos, a master's in occupational medicine from the University of Manchester and a postgraduate certificate in infection control from the University of Essex. She is a Fellow of the Faculty of Public Health National Postgraduate Medical College of Nigeria. Dr Okwor is the Co-Chair of the Mpox GDG.

For DOI, see the Annex.



## Chloe Orkin

Chloe Orkin is Professor of Infection and Inequities, Director of the SHARE Research Collaborative for Health Equity, and Dean for Healthcare Transformation at Queen Mary University of London (QMUL). Her clinical practice is at Barts Health NHS Trust. She was awarded Member of the Order of the British Empire for service to the National Health Service in 2024. She focuses on long-acting HIV treatment, mpox and equitable inclusion in research. She is a scientific advisor to the Medicines Patent Pool. Previous leadership roles include clinical advisor to WHO Europe for mpox (2022–2023), Chair of the British HIV Association (2016–2019), Medical Women's Federation President (2021–2023), IAS Governing Council (2020–2024) and Academic EDI Lead Faculty of Medicine and Dentistry QMUL (2021–2024).

For DOI, see the Annex.



## Diamantis Plachouras

Diamantis Plachouras is an infectious diseases physician with experience in clinical infectious diseases, infection control and antimicrobial stewardship. Since 2012, he has been working at the European Centre for Disease Prevention and Control (ECDC) in the disease programme for AMR and health care associated infections. Since January 2020, he has been involved in the ECDC response team for the COVID-19 pandemic as an expert on IPC. He received his medical diploma in 1994 and a doctorate degree in medicine at the University of Athens, Greece. He specialized in internal medicine in the United Kingdom and Greece and, subsequently, in infectious diseases.

For DOI, see the Annex.



## Priscilla Rupali

Priscilla Rupali is a professor in the Department of Infectious Diseases at Christian Medical College (CMC) Vellore in South India. She has worked as a senior fellow in the Department of Adult Infectious Diseases at Auckland City Hospital, New Zealand, and has a diploma in tropical medicine and hygiene from the Universidad Cayetano Heredia at Lima, Peru. She runs a very popular clinical tropical medicine course at CMC Vellore annually which provides lectures, bedside sessions and laboratory sessions by internationally acclaimed faculty. She has also been faculty of the Fellowship in HIV Medicine. She has undergone formal training in transplant infectious diseases at the Henry Ford Hospital in Detroit, Michigan, and subsequently was instrumental in establishing transplant-related services in her hospital and founder of the Transplant Infectious Diseases Conference in Vellore, Chennai and Ludhiana.

For DOI, see the Annex.



## Nadia Sam-Agudu

Nadia Sam-Agudu is a clinician-scientist and Professor of Pediatrics in Infectious Diseases and the Director of the Global Pediatrics Program at the University of Minnesota Medical School, USA. Her research and public health work is almost exclusively focused in West and Central Africa, where she serves as Senior Research Faculty and Senior Technical Advisor for Pediatric and Adolescent HIV at the Institute of Human Virology Nigeria, and a faculty of the Department of Pediatrics and Child Health at the University of Cape Coast in Ghana. She has over 20 years' experience in conducting maternal and child health research in several African countries, and nearly 15 years' experience implementing pediatric HIV programs in Nigeria.

Prof. Sam-Agudu's research focuses on implementation science methods for the prevention and treatment of major infectious diseases affecting children in African countries, such as malaria, HIV, TB, COVID-19, mpox. Her work also provides evidence and supports advocacy for addressing the needs of children and pregnant/breastfeeding women during disease outbreaks and in pandemic responses. She is a member of the Nigeria Implementation Science Alliance (NISA), the Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) and leads the Central and West Africa Implementation Science Alliance (CAWISA). Prof. Sam-Agudu has been a member of several working groups and clinical guideline committees regarding pediatric/adolescent HIV and maternal and child health in Nigeria, regionally with the Africa Centers for Disease Control and Prevention, and globally with the World Health Organization and the Global Alliance.

For DOI, see the Annex.



## Beate Sander

Beate Sander, RN, MBA, MEcDev, PhD, holds a Tier 1 Canada Research Chair in Economics of Infectious Diseases, is a senior scientist at the University Health Network (UHN) and the Inaugural Chair of UHN's Collaborative Centre for Health Systems and Policy Research. She is a professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, and holds appointments as Adjunct Senior Scientist at ICES (formerly, Institute for Clinical Evaluative Sciences) and Adjunct Scientist at Public Health Ontario.

Dr Sander is an internationally recognized leader in infectious disease economics with extensive expertise in health economics and simulation modelling. Her research focus is on assessing the cost-effectiveness of infectious disease interventions using simulation modelling, integrating equity considerations into economic evaluations, and estimating the burden of infectious diseases using population-based data.

Dr Sander is an expert member of advisory bodies, including Canada's National Advisory Committee for Immunization, where she chaired the Economics Task Group and co-chaired the Economic Guidelines Task Group – setting the standard for conducting economic evaluations for vaccines in Canada. She held several leadership roles during the COVID-19 pandemic, leading timely evidence generation and knowledge mobilization. Dr Sander is a Past President of the international Society for Medical Decision Making.

For DOI, see the Annex.





## Elena Sendagorta

Elena Sendagorta holds a PhD in medicine and surgery from Autónoma University of Madrid, where she is currently a professor. She develops her health care work as a specialist in dermatology at University Hospital La Paz, where she directs the care of dermatological inpatients. She is specialized in skin infections and STD, particularly HPV. She is also a researcher and a member of the CIBER infectious diseases of the ISCIII and of the Spanish AIDS Research Network. She is involved in many research projects, mainly related to severe cutaneous adverse reactions and the prevention of HPV dysplastic lesions in people living with HIV.

For DOI, see the Annex.



## Shalini Sri Ranganathan

Shalini Sri Ranganathan is a specialist in pharmacology and paediatrics at the University of Colombo, Sri Lanka. She has over 20 years' experience in both pharmacology and paediatrics. Since 2007, she has regularly served as a member on the WHO Expert Committee on Selection and Use of Essential Medicines. She has won numerous medals and awards during her professional career for academic excellence and research. Her main interests are essential medicines for children, antimicrobial utilization, access to medicines, pharmacovigilance, paediatric dosage forms and rational use of medicines. She is a member of editorial boards of journals in Sri Lanka including the *Ceylon Medical Journal* and *Ceylon Journal of Medical Sciences*. She has authored over 80 publications.

For DOI, see the Annex.



## Mark Sobsey

Mark D Sobsey, is currently a part-time research professor and previously a distinguished tenured professor in the Department of Environmental Sciences and Engineering, Gillings School of Global Public Health University of North Carolina at Chapel Hill, since 1974. His 50+ year academic career in environmental health microbiology and IPC has addressed a broad range of issues in health-related environmental microbiology and technology, IPC, disinfection, microbial detection and assay methods, and water-sanitation-hygiene (WASH) research, policy, practice and service. He is an advisor to WHO, the Food and Agriculture Organization, CDC, US Environmental Protection Agency, Water Environment Federation,



American Water Works Association, National Water Research Institute and other organizations.

For DOI, see the Annex.



## Joseph Tannous

Joseph Tannous is a certified infection control specialist with over 16 years' expertise in IPC across diverse health care settings. He holds a master's in hospital risk management and has been certified by the Certification Board of Infection Control (CBIC) since 2010, serving as an item writer and reviewer for CBIC since 2023. Throughout his career, Joseph has played a pivotal role in developing, implementing and leading infection control programmes, and the commissioning of new health care facilities. Internationally, he has advised WHO on missions to assess Ebola preparedness in multiple countries and actively participates in the Saint Jude Global Infectious Program in Memphis. Joseph has presented his research at major conferences such as ICPIC and APIC, where his contributions to infection control have gained broad recognition. He currently serves as an Infection Control Consultant with Emirates Health Services, UAE Ministry of Health and Prevention, and is a member of the UAE National Infection Control Committee.

For DOI, see the Annex.



## Valdilea Veloso

Valdilea Veloso, MD, PhD, is Director of the Evandro Chagas Clinical Research Institute, Brazil. She is co-PI of the FIOCRUZ Clinical Trial Unit, ACTG and HPTN co-investigator, and the PI of the Iniciativa Profilaxis Pre-Exposición study at FIOCRUZ. She is a team member of two ACTG TB-related protocols: A5221 and A5253. She is a member of the Brazilian Ministry of Health advisory committees for antiretroviral therapy and prevention of mother-to-child-transmission. She has served on The Global Fund Technical Review Panel and as UNAIDS consultant for implementation of HIV/AIDS care programmes in several developing countries. Her research interests focus on the optimization of antiretroviral therapy and the access to antiretroviral therapy in resource-limited settings.

For DOI, see the Annex.



## Mija Ververs

Mija Ververs, MMed, MPH, RD, is an accomplished professional with extensive expertise in nutrition and public health. She earned her degrees in nutrition (1985) and medicine (1991) in the Netherlands and completed a master's in public health (1997) at the London School of Hygiene & Tropical Medicine. Currently, she is a senior associate at the Center for Humanitarian Health at Johns Hopkins Bloomberg School of Public Health and a visiting health scientist at CDC.

With over 35 years' dedicated service, Mija has collaborated with more than 15 prominent organizations, including Médecins Sans Frontières, Action Contre la Faim, Save the Children, the International Committee of the Red Cross, IFRC and United Nations bodies (WHO, UNHCR, UNICEF, Global Nutrition Cluster), as well as government and academic institutions. Her primary focus encompasses public health and nutrition (malnutrition, infectious disease management, micronutrient deficiencies, etc.). Mija has worked in humanitarian settings across more than 25 countries affected by conflict and natural disasters. Over the past decade, she has specialized in infectious diseases related to breastfeeding and breastmilk, and nutritional care during outbreak responses (e.g. Ebola, mpox, COVID-19).

For DOI, see the Annex.



## Henry de Vries

Henry de Vries is dermatologist-venereologist with expertise in skin infections, especially STIs. In 2010 he was appointed Professor of Skin Infections at the University of Amsterdam and he is a Fellow of the Royal College of Physicians of London. He is currently employed at the Public Health Service Amsterdam Centre for Sexual Health where he leads a research group including 15 PhD students in close cooperation with the public health laboratory and research department. He is also appointed as staff member at the Department of Dermatology at the Amsterdam University Medical Centres, the Netherlands. In 2021 he organized the STI & HIV World Congress as President of the International Society for STD Research and he was Scientific Chair for the International Union Against STI 2018 World Congress in Dublin. He co-authored over 300 PubMed-registered publications on various topics including mpox, lymphogranuloma venereum, syphilis, gonorrhoea and leishmaniasis. In 2020 and in 2022 he was awarded the Bio Art & Design Award in joint projects with artists.

For DOI, see the Annex.



## Ian Woolley

Ian Woolley, MBBS, DTMH, MD, FRACP, is the Deputy Director of Infectious Diseases and Director of HIV Medicine at Monash Health in Melbourne, one of Australia's largest health networks, serving more than 1.5 million people. He has 20 years' experience as an infectious diseases physician, with sub-specialty interests in the care of people with HIV. He is an experienced clinical trialist, and has served on the Clinical Research Committee for the Australasian Society of Infectious Diseases, and on grant review committees for the European Union. He has supervised many trainees and junior staff, through specialist training and undergraduate and higher degrees by research. He has published over 170 peer-reviewed publications. He is the infectious diseases editor for the *Internal Medical Journal*, the *Journal of the Royal Australasian College of Physicians*, and has served on the editorial boards of *AIDS*, *BMC Infectious Diseases* and *Infectious Diseases and Therapy*.

For DOI, see the Annex.



## Steven Yeh

Steven Yeh currently is currently Professor of Ophthalmology and the Stanley Truhlsen Jr Chair, Director of Retina and Uveitis at the Truhlsen Eye Institute, University of Nebraska Medical Center. After undergraduate training at the Massachusetts Institute of Technology, Dr Yeh attended Baylor College of Medicine for medical training, where he then completed an ophthalmology residency. He then pursued fellowship training in uveitis and medical retina at the National Institutes of Health, followed by a fellowship in retinal surgery at Oregon Health and Science University.

Dr Yeh currently leads a clinical service, education and research programme that includes the clinical care and study of uveitis, retinal disease and global ophthalmic health. He and his research team have published numerous articles on infectious diseases of the eye, suprachoroidal drug delivery and the pathogenesis of eye disease associated with high consequence and emerging infectious pathogens including Ebola, Lassa fever, COVID-19 and mpox. More recently, he has provided care and investigated the spectrum of uveitis in Ebola survivors in the United States, West Africa and Central Africa.

Recently, Dr Yeh and his team have been developing vision health systems strengthening programmes, particularly vitreoretinal surgery and clinical research capacity in West Africa. In addition, Dr Yeh has been leading a programme to implement artificial intelligence technology for diabetic retinopathy detection in rural and urban

settings, utilizing technology to bridge health disparities within the United States and abroad.

Dr Yeh is a member of the American Academy of Ophthalmology, American Society of Retina Specialists, Macula Society, Retina Society, American Uveitis Society and WHO Global Outbreak Alert and Response Network. Dr Yeh is currently funded through the National Institutes of Health, USAID, Macula Society and philanthropic foundation support.

For DOI, see the Annex.

## Annex

Name	Conflict of interest
<b>Pierre Abi Hanna</b>	No conflict of interest identified.
<b>Nawal Al-Kaabi</b>	No conflict of interest identified.
<b>Mary Adanma Alex-Wele</b>	No conflict of interest identified.
<b>Meaghan Allen</b>	No conflict of interest identified.
<b>Javier Bellocq</b>	No conflict of interest identified.
<b>Lars Bode</b>	Family Larsson-Rosenquist Foundation, University of California San Diego (US\$ 4 million endowment), Chair of Collaborative Human Milk Research, current. Decision: no action needed.
<b>Andre Bulabula</b>	No conflict of interest identified.
<b>Shama Cash-Goldwasser</b>	No conflict of interest identified.
<b>Mark Cotton</b>	No conflict of interest identified.
<b>Jake Dunning</b>	No conflict of interest identified.
<b>Tom Fletcher</b>	Research funding for transmission of high consequence pathogens including mpox: UK NIHR HPRU and Pandemic Institute (£300 000), 2021–2025. Decision: no action needed.
<b>Esther Freeman</b>	Grant recipient: International League of Dermatologic Societies on emerging infectious registry (US\$ 50 000). Committee member: American Academy of Dermatology emerging infections taskforce (unpaid). British Journal of Dermatology: editor (US\$10 000). Decision: no action needed.
<b>Carole Fry</b>	Employment: P4 Technical Officer HQ QOC and HQ UHL UHC Decision: no action needed.
<b>Michelle Giles</b>	Member of the Australian Technical Advisory Group on Immunization (approximately US\$ 7000), current. Decision: no action needed.
<b>Beatriz Grinsztejn</b>	No conflict of interest identified.
<b>Ahmed Hakawi</b>	No conflict of interest identified.
<b>Lisa Hensley</b>	No conflict of interest identified.
<b>Prince Imani-Musimwa</b>	No conflict of interest identified.
<b>Kushlani Jayatilleke</b>	No conflict of interest identified.
<b>Nagwa Khamis</b>	No conflict of interest identified.
<b>Jason Kindrachuk</b>	Received grant funding (as both PI and co-applicant) from the Canadian Institutes of Health Research, Horizons Europe and the Canadian Biomedical Research Fund (current). All funds are dedicated to research, not personal salary. Decision: no action needed.
<b>Fernanda Lessa</b>	No conflict of interest identified.
<b>Yugo Li</b>	No conflict of interest identified.
<b>Laurens Liesenborghs</b>	No conflict of interest identified.

<b>Kalisvar Marimuthu</b>	Received funding from Singapore's interim Communicable Disease Agency to support travel expenses to WHO meetings. Decision: no action needed.
<b>Geeta Mehta</b>	Contracted with WHO South-East Asia Regional office to complete a situation analysis of IPC, quality and patient safety and road map in the WHO South-East Asia Region, 2021 Decision: no action needed.
<b>Graeme Meintjes</b>	No conflict of interest identified.
<b>Sharon Nachman</b>	Site for ACTG 5418 MPOX treatment trial of tecovirimat, Suny Stony Brook (\$25,000 for patient enrolment on study), ceased. Decision: no action needed.
<b>Grace Ndeezi</b>	No conflict of interest identified.
<b>Pius Okong</b>	No conflict of interest identified.
<b>Tochi Okwor</b>	No conflict of interest identified.
<b>Chloe Orkin</b>	Honoraria: GILEAD (> £10 000), ViiV Healthcare (> £10 000), MSD (£5000), Balvarian Nordic (£2000). Research support: GILEAD (> £600 000), ViiV Healthcare (> £2 million). All current. Decision: no action needed.
<b>Diamantis Plachouras</b>	Employment: European Centre of Disease Prevention and Control (current) Decision: no action needed.
<b>Priscilla Rupali</b>	No conflict of interest identified.
<b>Nadia Sam-Agudu</b>	Research support: European Commission - VERDI grant (€110 000), current. Decision: no action needed.
<b>Beate Sander</b>	No conflict of interest identified.
<b>Elena Sendagorta</b>	No conflict of interest identified.
<b>Mark Sobsey</b>	No conflict of interest identified.
<b>Shalini Sri Ranganathan</b>	No conflict of interest identified.
<b>Joseph Tannous</b>	No conflict of interest identified.
<b>Valdilea Veloso</b>	No conflict of interest identified.
<b>Mija Ververs</b>	No conflict of interest identified.
<b>Henry de Vries</b>	Funding for clinical research: RIVM, national public health governmental organization (€250 000). Decision: no action needed.
<b>Ian Woolley</b>	No conflict of interest identified.
<b>Steven Yeh</b>	No conflict of interest identified.







For more information, please contact:

Emerging Diseases Clinical Assessment and Response Network  
World Health Organization  
Avenue Appia 20  
CH-1211 Geneva 27  
Switzerland

Email:  
[CMTM@who.int](mailto:CMTM@who.int)